The focus of this session was on the proposed USEPA Endocrine Disruption Screening Program (EDSP) Tier 2 testing protocols. Tier 2 tests have been developed to evaluate the potential impacts of endocrine disrupting chemicals (EDCs) over the life cycle across organisms representing vertebrate and invertebrate classes. Key aspects of these Tier 2 testing protocols rely on selecting appropriate measurement end points to reveal differential sensitivity and adverse impacts across an organism's life stages. To this end, certain Tier 2 tests utilize a multigenerational protocol, which detect both short-and longterm effects. However, multigenerational testing protocols can be time consuming and costly. As such, other testing protocols have also been considered, including partial lifecycle and extended one-generation tests. Regardless of the specifics of the multigenerational protocol, it is critical to identify key measurement end points that are responsive, reliable, and repeatable indicators of exposure to endocrine disrupting chemicals; these measures should also provide information to enable initial assessments Presentations in this session considered the strengths and weaknesses of the Tier 2 assays across several classes of organisms, and provided an industry perspective on Tier 2 testing. The interactive panel discussion provided an interesting perspective that balanced regulatory needs for reliable testing protocols that are highly repeatable and utilize consistent indices of exposure and adverse effect.
INTRODUCTION
There are a number of components that constitute the USEPA Endocrine Disruption Screening Program (EDSP) that, subsequent to priority setting candidate chemicals, include screening and testing programs to be implemented through Tier 1 and Tier 2 testing protocols.
The goal of Session Three of the Society of Environmental Toxicology and Chemistry (SETAC) North America Focused Topic Meeting: Endocrine Disruption (February 4 -6, 2014) was to provide an overview of the strengths and weaknesses of the Tier 2 test protocols across a range of species and classes of organisms; and importantly to integrate the industry perspective into the conduct and efficacy of these testing protocols to assess endocrine disrupting compounds 
USEPA's Endocrine Disruptor Screening Program Tier 2 Ecotoxicology Test Methods
by Leslie Touart 1 USEPA established the Endocrine Disruptor Screening Program (EDSP) in response to a US Congressional mandate "to determine whether certain substances may have an effect in humans that is similar to an effect produced by a naturally occurring estrogen, or such other effects as USEPA may designate" (21 U.S.C. 346a(p)) (USEPA 2011) . As part of the EDSP, USEPA is validating assays to identify and characterize the endocrine activity of pesticides, commercial chemicals, and environmental contaminants, specifically in relation to estrogen, androgen, and thyroid hormones. This talk presented a brief historical summary of the development and validation of the candidate test methods including a mammalian two-generation test, a Japanese quail two-generation test, the Larval Amphibian Growth and Development Assay (LAGDA), a medaka multi-generation test, and an invertebrate test. Although a medaka multigeneration test was the principal fish method considered, an abbreviated medaka reproduction (extended one-generation) test was also proposed. Additionally, a mysid two generation toxicity test is recommended as the preferred invertebrate in vivo Tier 2 EDSP test, but a harpacticoid copepod reproduction and development test was also considered as a potential alternative or option. The reasoning and judgments leading to the various studies that were conducted as part of the development, demonstration, and validation of the various test methods was discussed. In addition, the outcome and recommendations of a FIFRA SAP review (USEPA 2013) (www.epa.gov/scipoly/sap/meetings/2013/june/062513minutes.pdf ) of the proposed methods and public comments of the revised methods were summarized and discussed. The current status of the final test guidelines, at the time, was presented.
The Proposed Tier 2 Medaka Extended One-Generation Reproduction Test (MEOGRT)

By: Kevin Flynn
The Medaka Extended One Generation Reproduction Test (MEOGRT) has been proposed as part of the Tier 2 testing within the USEPA EDSP. As part of definitive Tier 2 testing, the MEOGRT should determine whether a substance adversely affects a test organism through endocrine-mediated pathways, and to quantitatively evaluate those effects incorporating exposure during the most sensitive life stages and provide the opportunity for identification of doseresponse effects. The MEOGRT characterizes the nature, likelihood, and dose-response relationship of apical adverse outcomes from potential endocrine disruption via estrogenic, androgenic, and possibly thyroid pathways. In general, to meet the goals of an EDSP Tier 2 test protocol, the MEOGRT encompasses all the life stages of at least one full generation (F1) including effects on fertility and mating, embryonic development, sensitive neonatal growth and development, and transformation from the juvenile life stage to sexual maturity. In addition, a anticipated to enter a public commenting period 2 . It is possible that in response to comments received both from internal and external stakeholders, the USEPA may change aspects of the protocol that would not have been presented at the SETAC North America Focused Topic Meeting (FTM) on Endocrine Disruption: Chemical Testing and Risk Assessment Approaches and Implications. However, it is not anticipated that fundamental changes to the structure of the test, for instance, starting exposure with adult F0 and continuing through a complete F2 generation, would occur after the commenting period.
Information that was used to arrive at the proposed replicate structure was summarized.
The MEOGRT has a 2:1 replication design: twice as many control replicates as each exposure replicate. For most of the test, there are 12 control replicates and 6 replicates in each of five exposure levels; however, during the reproductive assessment, the replication doubles so there are 24 control replicates and 12 replicates in each of the five exposure levels. A power analysis based upon Monte Carlo simulation of fecundity data was done that provided the necessary information to make recommendations regarding replicate structure within the MEOGRT ( Figure   1 ). Note that at 12 control replicates/6 exposure replicates per treatment, there is a small but noticeable probability of not detecting a reduction of 50%, about a 75% probability at detecting a reduction of 40%, a less than 50% chance at detecting a reduction of 30%, and a very little chance at detecting a reduction of 20%. At 24 control replicates/12 exposure replicates per treatment, the probability of not detecting a reduction of 40% or greater is near zero, and there is probability of greater than 80% of detecting a reduction as low 30%. During discussions on replicate structure of the MEOGRT, consideration was given not only to the power analysis, but also to the possibility of mortality, especially in the control replicates. It has been our experience that a very small percentage of the adults, irrespective of treatment, may die, and in addition, even with skilled technicians, there is a possibility of handling-induced mortalities as well. To be conservative, 12 breeding pairs (replicates) in treatments and 24 control breeding pairs (replicates) was chosen to mitigate the consequences to statistical power.
The MEOGRT provides data about the primary apical endpoint of reproduction, as well as the toxicity endpoints of growth, hatch, survival, and liver pathology, and finally data providing insight into adverse outcome pathways (secondary sexual characteristics, vitellogenin gene expression and gonad pathology). This data is either a ratio, ordinal, or continuous in nature.
Typical control values, the expected minimum and maximum values, and the proposed acceptance criteria are presented for each of the endpoints specified in the MEOGRT below (Table 1) . Data from future MEOGRTs that fail to meet the acceptance criteria put the validity of the individual test at risk by potentially reducing power to unacceptable levels or loss of entire exposure levels.
Based upon the molecular initiating event of an adverse outcome pathway, a certain pattern of responses in the above endpoints might be expected (Table 2 ). These data expectations provide a potential means to identify the adverse outcome pathway(s) that an unknown EDC activates to produce a negative biological impact. While there are substantial data gaps for various adverse outcome pathways, the expected outcomes based upon the molecular initiating event are presented in Table 2 .
In conclusion, the presentation of the MEOGRT protocol at the SETAC FTM on Endocrine Disruption was intended to provide a summary of the protocol, rationale for the proposed replication structure, typical output data from the protocol, and the impacts on the measured endpoints based upon molecular initiating event. We also assert that the MEOGRT protocol fulfills the EDSTAC-defined purpose of a Tier 2 test in that it 1) includes endpoints to assess whether a test substance adversely affects a test organism through endocrine-mediated The LAGDA protocol describes a chronic toxicity test with an amphibian species that considers growth and development from fertilization through the early juvenile period 3 . It also enables measurement of a suite of other endpoints that allows for diagnostic evaluation of endocrine disrupting chemicals or other types of developmental and reproductive toxicants. The LAGDA is a relatively long-term assay (normally 130 days or longer) that assesses early development, growth, and partial reproductive maturation. The test is designed to detect both endocrine and non-endocrine mechanisms by including diagnostic endpoints specific to key endocrine mechanisms. It should be noted that prior to development of the LAGDA, no validated assay existed which could serves this function for amphibians. the LAGDA assay (USEPA, 2013) . The following chemicals were evaluated across individual or multiple laboratories: prochloraz (aromatase inhibitor, AR agonist), 4-tert-octylphenol (ER agonist), 17-β trenbolone (AR agonist), and benzophenone-2 (ER agonist, TPO inhibitor).
Prochloraz was tested in four labs, and 4-tert-octylphenol was tested in three labs. Trenbolone and benzophenone-2 were tested in single laboratories and these studies serve to demonstrate the responsiveness of the LAGDA to additional modes of action.
The LAGDA proved to be an effective test model. All four chemicals produced endocrine-related effects. Of the two chemicals available for inter-laboratory comparison, prochloraz resulted in thyroid gland pathologies consistent with a hypothyroid condition in 3 of the 4 labs, and vitellogenin (VTG) induction and gonad/reproductive duct pathologies were noted in all 4 laboratories. The second chemical, 4-tert-octylphenol, produced thyroid gland pathologies consistent with a hypothyroid condition and delayed development in only 1 of the 3 laboratories. However, VTG production and mild gonad/reproductive duct pathologies were observed in all laboratory studies. 17-β Trenbolone and benzopehone-2, although only tested in single laboratories, produced endocrine-related effects involving the thyroid gland, delayed metamorphosis, VTG production and reproductive tract pathologies.
Validation of the Mysid Two-Generation Toxicity Test for the Regulatory Testing of Endocrine Active Compounds, by Tim Verslycke
This presentation provided a summary of the validation results for the mysid twogeneration toxicity test (MTTT) which is being proposed as a Tier 2 invertebrate assay in USEPA's EDSP. Full validation results for the MTTT as well as the harpacticoid copepod development and reproduction test (HCDRT), which was evaluated as a potential alternative to Invertebrates comprise 95% of the world's animal species (Wilson 1988) , and certainly a larger percentage of the Earth's total animal abundance. Many invertebrate toxicity test protocols are routinely used in regulatory testing; however, few have been designed with endocrine-specific endpoints in mind. Although many aspects of invertebrate physiology and life cycle are known to be under endocrine control, the hormones produced and used by invertebrates are not directly analogous to those of vertebrates. For example, crustaceans and other ecdysozoans account for more than 75% of all known animal species, yet they rely largely on invertebrate-specific ecdysteroid and juvenile hormones to regulate their physiology (Chang 1993; deFur et al. 1999; Subramoniam 2000) . On the other hand, crustaceans have true endocrine glands derived from epithelial tissue and functioning similar to vertebrate glands (deFur 2004) and their endocrine systems are relatively well understood compared to those of other invertebrates (Oehlmann and Schulte-Oehlmann 2003; LeBlanc 2007) . Given that endocrine disruption has been reported in crustaceans (OECD 2006) , an invertebrate test method that uses crustaceans for evaluating potential effects of endocrine disrupting chemicals (EDCs) is relevant.
Mysid crustaceans have been used in regulatory (and other) toxicity testing for more than 30 years and standard testing protocols have been developed for several species. Beyond certain insect growth regulators (IGRs), there have been few direct links between potential EDCs and endocrine disruption in mysids. Still, mysids have the ecological relevance and sensitivity to stressors required of a taxon that would be suitable for evaluation of endocrine disruption in marine and estuarine invertebrates and could serve as a surrogate for other crustacean species.
Further, the proposed test species, Americamysis bahia, has widespread availability, is relatively easy to culture, has a short life cycle (17-20 days), and has been widely used in toxicity testing. Finally, our knowledge of hormone regulation in mysids continues to grow and several EDCrelated endpoints in mysids have been proposed over the last decade (Verslycke et al. 2004 Ghekiere et al. 2005; 2006a; 2006b; Yokota et al. 2011) .
McKenney (2005) first demonstrated transgenerational effects in A. bahia using a two-generation exposure protocol. These studies led to the development of the proposed Tier 2 invertebrate assay. The proposed MTTT is a relatively long-term assay (normally 60 days or longer) that assesses early development, growth, and reproduction in two generations. It is an extension of existing standard practice for conducting a mysid life-cycle test (ASTM 2004; McKenney 1986 McKenney , 1998 and Nimmo et al. 1977, 1978) and is intended to serve as a higher tier test with an aquatic arthropod for collecting definitive concentration-response information on adverse effects suitable for use in ecological risk assessment. The MTTT guideline includes 25 different endpoints (8 growth, 11 reproduction, and 9 survival endpoints), some are recorded per mysid or composite of mysids, some are recorded per breeding pair, and some are recorded per replicate tank.
The MTTT guideline was used in demonstration and optimization studies using a number of endocrine-active chemicals (fenoxycarb, 3,5-dichlorophenol, fipronil, prochloraz, flutamide, ketaconazole, 4-tert-octylphenol, lindane, atrazine, perfluorodecanoic acid) in two different laboratories. Subsequently, the MTTT guideline was used in an inter-laboratory validation study with three participating laboratories and using three endocrine-active chemicals (lindane, vinclozolin, 4-tert-octylphenol) . Two out of the three laboratories were able to successfully execute the draft method. Large inter-laboratory and intra-laboratory variability was observed in the control endpoint responses. Significant differences were also observed in lab proficiency as estimated by the variability in the endpoint responses in the control groups, indicating difficulties in the transferability of the MTTT between laboratories. Further, where the same chemical was A number of strengths of the MTTT were highlighted during the validation studies.
Laboratories have established experience with A. bahia and were generally able to successfully perform the MTTT within the recommended acceptability criteria. Further, the MTTT can be conducted in continuous or intermittent flow ensuring consistent water quality and chemical exposure concentrations. Also, control variability for several endpoints indicates that these should be able to detect significant adverse effects with adequate statistical power. Finally, common population modeling approaches can be employed based on the data obtained in the MTTT to estimate population-level effects (Raimondo and McKenney 2005) and several mechanistic endpoints (e.g., vitellin and hormone levels, hormone receptor expression) could be added to the MTTT to allow for the collection of mechanistic data.
Similarly, a number of limitations of the MTTT were highlighted during the validation studies. Considerable variability was observed in endpoint responses between different laboratories, resulting in reduced power to detect significant differences. Some of the endpoints were consistently non-responsive (e.g., sex ratio, time to maturation), and their value may need to be evaluated further. There was a lack of treatment-related responses and responses were inconsistent between laboratories. Several aspects of the MTTT are time-consuming and resource demanding. Specifically, the addition of a second generation significantly adds to the time and resources required to perform the MTTT and the value of the additional information obtained from the second generation was not obvious. Finally, the appropriateness and adequacy of the current Tier 1 screen for identifying chemicals that may interfere with invertebrate hormone axes or the endpoints measured in the MTTT remains unclear since Tier 1 screening is The purpose of the Tier 2 Japanese Quail (Coturnix japonica) Avian Toxicity Test is to detect both short and long term impacts from exposure to Endocrine Disrupting Chemicals (EDCs). effects on reproductive and metabolic endocrine function. Moreover, because the Japanese quail has the same neuroendocrine circuitry regulating reproduction as other avian species, any impact would be translatable to field birds. Behavioral impacts observed in Japanese quail would be indicative of potential greater impacts on songbirds because the song control system is steroid dependent as are the neural systems that modulate singing behavior. Because the F1 (first generation) birds are exposed both via maternal deposition and from the diet (same treatments as their parents), they would be impacted by endocrine disruption during embryonic development and sexual differentiation as well as experiencing any impacts due to endocrine disruption during activation of reproduction during maturation and in adults. Finally, the F2 (second generation) is exposed to maternally deposited EDCs, thereby exhibiting effects of endocrine disruption during embryonic development. As such, the importance of the F2 generation is to reveal potential transgenerational effects and isolate embryonic effects of EDCs.
The Japanese quail is a precocial bird that has advantages for a multigenerational testing protocol because this species is relatively domesticated, rapidly maturing, easily maintained in the laboratory, and is a well-characterized avian model. Studies have been conducted to inform the design of an avian two-generation testing protocol and to ascertain key measurement endpoints that provide reliable indicators of EDC exposure. These studies have included egg injection and several types of dietary studies that have considered a range of compounds. Egg injection studies take advantage of avian embryonic development in the egg, independent of parental input. As such, egg injection studies mimic maternal deposition of chemicals, providing an opportunity to dose the embryo with known concentrations of compound and track effects throughout ontogeny. These studies have shown impacts of EDCs on reproductive and metabolic endocrine systems, behavior, and heart function, especially with exposure during embryonic development (Ottinger et al 2005; 2009; Ottinger and Dean, 2011) . Findings from comparison of existing studies reveal that many EDCs do impact avian species in support of observations of wild populations (Rattner et al, 2004) . These studies also emphasize the unique characteristics of avian species, which must be considered by a testing protocol, including high body temperature, migration associated energy demands, precocial and altricial birds, high metabolic rate, and mechanisms and role of steroid hormones in sexual differentiation. In addition, potential sources of variability occur due to strain differences and between species relative to sensitivity to EDCs.
Analyzing core endpoints of survival, growth, and reproduction across generations will reveal potential impacts on reproductive, metabolic/thyroid systems, and adrenal/stress axes as well as general toxicity. It is important to assess measurement end points reflective of neural mechanisms regulating reproductive endocrine function and behavioral response, metabolic and stress axis function, and functional measures indicative of adverse physiological outcomes.
Future applications will use these data to assess risk across the wide range of breeding strategies and diversity of life histories with consideration of sensitivity and period(s) of vulnerability in order to protect avian populations.
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Status of OECD work on the Development of Harmonized Test Methods for Endocrine
Disrupters, by: Anne Gourmelon
The protection of human health and the environment from endocrine disrupters is currently a high priority for regulatory authorities in most OECD countries/regions, and it has been proposed by UNEP as a SAICM (Table 5) , and a few non OECD test methods. The updated CF is attached as an annex to the
Guidance Document on Standardized Test Guidelines for Evaluating Chemicals for Endocrine
Disrupters (OECD, 2012a) . The revised description of the five levels of the draft CF is as follows:
 Level 1. Existing data and non test information  Level 2. In vitro assays providing data about selected endocrine mechanism(s)/pathway(s)  Level 3. In vivo assays providing data about selected endocrine mechanism(s)/pathway(s)  Level 4. In vivo assays providing data on adverse effects on endocrine relevant endpoints  Level 5. In vivo assays providing more comprehensive data on adverse effects on endocrine relevant endpoints over extensive parts of the life cycle of the organisms.
Information/tools from lower levels can be used to determine what specific higher level tests are needed for a specific chemical to increase evidence that it is/it is not an endocrine disrupter. This
approach is illustrated in the Guidance Document on Standardized Test Guidelines for Evaluating
Chemicals for Endocrine Disruption (OECD, 2012a) 
; guidance document on standardized test guidelines for evaluating chemicals for endocrine disruption
The Guidance Document No. 150 in the OECD Series on Testing and Assessment (OECD, 2012a ) was developed to support regulatory authorities' decisions related to the hazard of specific chemicals and toxicologically-relevant metabolites when they receive test results from a Test Guideline or draft Test Guideline for the screening/testing of chemicals for endocrine disruption. The guidance is worded to permit flexible interpretation in the context of different domestic legislation, policies and practice. It also provides guidance on how to interpret the outcome of individual tests, taking into account existing information, and how to increase evidence on whether or not a substance may be an endocrine disrupter. It recommends test 
Tier 2 EDSP Assays Viewed Through the Lens of Ecological Risk Assessment, by: Allen Olmstead
Ecological risk assessment is the process through which the likelihood that adverse effects in the environment occur due to a stressor. Generally for chemical substances, assessments are made at the level of the individual on processes of survival, growth, and reproduction with the 6 Note from the Guest Editor: Since the Focused Topic Meeting was held, OECD guideline 240 of the Medaka Extended One Generation Medaka Reproduction Test (MEOGRT) and OECD guideline 241 of the Larval Amphibian Growth and Development Test (LAGDA) have been finalized (OECD 2015a (OECD , 2015b assumption that by safeguarding these, populations would be protected from adverse effects.
Endocrine toxicity represents one of many means through which these processes may be affected.
While currently a large battery of ecotoxicology tests is employed to assess the hazard, these are not tailored specifically to endocrine toxicity. The EDSP should evaluate hazard that is not covered by current testing. The Tier 2 EDSP assays should be evaluated based on what additional hazard information that has a meaningful impact on ecological risk assessment is generated beyond that from current test guidelines. Further, the endpoints measured in these test should be optimized with respect to their utility in evaluating ecological risk.
The Contract Lab Perspective on Higher Tier Endocrine Tests Part 2, by: Hank Krueger
Higher tiered endocrine testing will be conducted in Contract Laboratories that will be challenged by the size and complexity of these studies. I would like to thank many contributors that expressed opinions and provided comments in preparing for this presentation. Their contribution represents many years of experience in the contract laboratory environment.
Translating the concepts of Tier 2 testing into reality provide many practical challenges that have not been thoroughly discussed or incorporated into guidelines. Among the challenges is the selection of test concentrations, physical constraints on our ability to achieve test concentration in test systems, finding ways to fill data gaps to have the necessary information for the design of Tier 2 tests, ways to improve Tier 2 tests, and managing projects with higher degrees of complexity.
When it comes to selecting test concentrations several issues need to be addressed. The first is to determine the range and spacing of concentrations. Knowing how high to test becomes critical, because it is desirable to be testing at levels that are free from the effects of general toxicity. Testing at concentrations that require separating classical effects of toxicity from endocrine effects should be avoided. While it is desirable to be testing at a maximum tolerated dose, defining that dose and achieving it experimentally can be difficult. Tier 1 testing used the criteria for setting the highest test concentration as 100 mg/L, the water solubility limit, or 1/3 the LC50 as an estimate of the maximum tolerated dose. While these high concentrations represent extreme levels, they may be very different from relevant environmental concentrations. This leads to a more general question of setting concentrations that are environmentally relevant for risk assessment or setting them to determine hazard. There is also the concern of low dose effects, which means more guidance will need to be provided to labs on how to set and space test concentrations.
There are physical limitations as to what can be done in laboratories. The chemicals that were chosen to develop the tests and then used in the test validation process were well studied and in most cases had desirable physical properties and modes of action. The chemicals selected for the validation of the Medaka 2-Gen study all were very soluble and for the most part were easy to deliver since the concentrations were well over 100 times their solubility limit. However, to test at concentrations near the solubility limit, the volumes of stock solutions that need to be prepared for testing become limiting. Other physical constraints on spacing of test concentrations occur for materials with very low solubility. In some cases, the distance between the limit of solubility and the analytical limit of quantitation (LOQ) may be too small to accommodate the desired range of concentrations.
Test systems used in aquatic toxicity tests have been designed to deliver concentrated stocks to mixing chambers where a clean source of dilution water (well water) is mixed with the stock ideally at a ratio of 1: ≤100 of stock solution to dilution water. Testing at water solubility limit means there is no dilution and that the highest test concentration receives nothing but the water stock prepared at the solubility limit. The worst case scenario for endocrine testing is the mysid 2-generation test which would consume 1600 L of stock per day. If the highest test concentration was 100 times lower than the solubility limit, then one would could prepare a water stock at the solubility limit and then dilute it 100 fold which would result in the consumption of only 16 L of stock per day, a much more manageable volume.
While a stock is being used on a test it must be stable. If a material degrades as a result of hydrolysis or photolysis, or is lost to the system through volatility or adsorption while the test is being conducted, then the use of a water stock is limited. This is one of the key reasons solvents have been used in aquatic toxicology. One can prepare a concentrated stock in solvent that is both stable and concentrated. There are guideline limits on how much solvent can be used in a test, with limits of 0.1 ml/L for general testing and 0.02 ml/L for endocrine tests resulting in 10,000 and 50,000 fold dilutions of stock, respectively. While solvents should be avoided they still can have a role when testing at concentrations near the solubility limit or when testing materials that are not stable in water stocks.
Contract labs are also concerned about the limited amounts of data that may be available when asked to conduct a Tier 2 test. Data gaps will exist that will need to be filled to design a larger scale test. Information from Tier 1 testing is limited. Tier 1 tests do not look at liver and kidney histology which are new endpoints for the Tier 2 test. How does one address these endpoints when selecting test concentrations? Designing higher tier endocrine tests involves taxonomic leaps of faith extrapolating data from rodent assays to fish, frogs, and birds; from fathead minnow to medaka, from mallard and bobwhite quail to Japanese quail, and from receptor to whole organism.
The Tier 1 Fish Short Term Reproduction Assay (FSTRA) is a 21-day assay using adult fathead minnows. While the study provides data on adults, data on sexual development from earlier stages of development are missing. Knacker et al (2010) demonstrates that for most modes of action for endocrine disruption in zebrafish, sexual development is the most sensitive stage to look for effects. Such data gaps demonstrate the need for pilot studies that are smaller and more focused experiments that provide additional information for designing a higher tiered test. Pilot studies may also incorporate newer techniques that provide better data and may provide enough information so that the Tier 2 test is not needed.
Lastly, endocrine testing raises new concerns as to how we manage studies in contract laboratories. Ron Biever of Smithers Viscient points out that in the past all that was needed in a project team was a chemist to evaluate exposure by measuring concentrations of test substances in water and a biologist to serve as a study director to oversee a test from start to finish, interpret results, and author a report. Endocrine studies have added a level of complexity that requires a more complex project management structure and have redefined the role of the study director. In addition to a biologist and chemist, other members of the project team now include individuals that specialize in the measurement and evaluation of biomarkers that include vitellogenin, steroids, determination of genetic sex, gene expression and histopathology. A statistician is also needed on the project team with all these additional endpoints and rigorous statistical analyses being required in the guidelines. The study director's new role is to integrate all these disciplines into one report and that will require very knowledgeable and experienced individuals.
CONCLUSIONS
Multigenerational tests provide critical information about the potential for impact by endocrine active compounds or EDCs over the life cycle across vertebrates and invertebrates.
These Tier 2 testing protocols rely on selecting appropriate measurement end points to reveal differential sensitivity and adverse impacts across an organism's life stages. Further, it is important to understand life stages that are most sensitive or vulnerable to the effects these environmental contaminants. It has become clear that traditional methods of assessing potential risk and impact to an individual or population may not reveal EDC associated adverse effects. As more is known about the timing and sensitivity of organisms to suspected EDCs, a suite of targeted measurement end points as part of an extended one generation or multigenerational test will augment estimated toxicity from measures such as toxic equivalency quotient (TEQ) or toxic equivalency factor (TEF). Finally, Tier 2 tests will detect both short-and long-term effects as well as other potentially long-term effects from epigenetic change. However, multigenerational testing protocols can be time consuming and costly. As such, other testing protocols have also been considered, including extending the one-generation test. Regardless of the specifics of the multigenerational protocol, it is critical to identify key measurement end points that are responsive, reliable, and repeatable indicators of exposure to endocrine disrupting chemicals; these measures should also provide information to enable initial assessments of risk translated from individual to potential population level effects across a variety of living organisms.
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